Biopharma firm Lipocine's Q3 net loss widens

Lipocine

06/11/2025 13:08

Overview

Lipocine Q3 net loss widens to $3.2 mln, impacted by increased R&D expenses

Royalty revenue from TLANDO sales was $115,000 in Q3 2025

Company's cash reserves decreased to $15.1 mln from $21.6 mln at end of 2024

Outlook

Lipocine expects top-line data for LPCN 1154 in Q2 2026

Result Drivers

INCREASED R&D EXPENSES - Higher R&D costs primarily due to ongoing LPCN 1154 Phase 3 trial for postpartum depression

RESEARCH AND DEVELOPMENT EXPENSES - were $2.7 million and $1.6 million, respectively, for the quarters ended September 30, 2025 and 2024

ROYALTY REVENUE - TLANDO sales contributed $115,000 in royalty revenue during Q3 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.59
Q3 Net Income
-$3.20 mln
Q3 Basic EPS
-$0.59


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lipocine Inc is $7.38, about 65.3% above its November 5 closing price of $2.56

Press Release: ID:nPn7PMXH3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)